REGISTERED
on 31 May 2022
Last Applicant/ Owned by
47-3 Banpodaero 39gil, Seochogu,
Seoul
KR
06579
Serial Number
90244106 filed on 09th Oct 2020
Registration Number
6747871 registered on 31st May 2022
Filing Basis
1. intent to use
2. use application currently
Disclaimer
NO DATA
YIPSCELL
pharmaceutical preparations for the treatment of musculo-skeletal disorders, damaged skin and tissue, and for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for treating and preventing knee cartilage and meniscus injuries and disorders, and for knee cartilage and meniscus regeneration; medicinal preparations for musculo-skeletal disorders, damaged sk Read More
Classification Information
Class [005]
Pharmaceutical Products
pharmaceutical preparations for the treatment of musculo-skeletal disorders, damaged skin and tissue, and for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for treating and preventing knee cartilage and meniscus injuries and disorders, and for knee cartilage and meniscus regeneration; medicinal preparations for musculo-skeletal disorders, damaged skin and tissue, and for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for treating and preventing knee cartilage and meniscus injuries and disorders, and for knee cartilage and meniscus regeneration; biochemical preparations for medical purposes, namely, for the diagnosis and treatment of musculo-skeletal disorders, damaged skin and tissue, and for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for treating and preventing knee cartilage and meniscus injuries and disorders, and for knee cartilage and meniscus regeneration; pharmaceutical preparations for the treatment of viral and infectious diseases, autoimmune diseases, kidney diseases, hepatic diseases, neurological diseases and bone diseases; stem cells for medical and veterinary purposes; cultured cells comprised of stem cells for medical use, namely, injection and impanation for treatment of cartilage and meniscus injuries; cells for medical use; cellular function activating agents for medical purposes; cell growth media for growing cells for medical use; reagent kits for medical purposes comprising chemical agents, skin, cartilage and other cells; culture media for cultivating human cells for use in augmentation of bone and other tissues for medical purpose using induced pluripotent cells and embryonic stem-like cells and other stem cells; kit containing chemical media additives being cell growth media for growing cells for medical and veterinary purposes; culture media for cultivating human cells for use in regenerative medicine, oncology, hepatology and hematology; chemical, biochemical, biological, and cell biological products for medical purposes, namely, induced pluripotent stem cells (iPSCs), cell media, cell culture supplements and reagents for cell suspension, cell growth and cell storage; medicines, pharmaceutical products and preparations for health care, namely, induced pluripotent stem cells (iPSCs) and iPSC cultures; cell cultures and cell culture systems for human cells and for medical purposes, namely, induced pluripotent stem cells (iPSCs) and freeze-conserved cells, and reagents for sub cultivation of the cells; intestinal epithelial cell preparations for the treatment of gastrointestinal diseases; pharmaceutical preparations to evaluate the toxicity, metabolism, drug absorption and compound efficacy of the small intestines; medicinal preparations to evaluate the toxicity, metabolism, drug absorption and compound efficacy of the small intestines; intestinal epithelial cells for medical purposes; pharmaceutical preparations, namely, live cells in the nature of smooth muscle cells, skeletal muscle cells, myocytes, fibroblasts, chondrocytes, adipocytes, fibromyoblasts, ectodermal cells, hepatocytes, organ cells, liver cells, kidney cells, cardiac cells, pancreatic islet cells, cells present in the intestine, stem cells, osteoblasts, cells forming bone or cartilage, hematopoietic cells, parenchymal cells, stroma cells, totipotent cells (iTC), pluripotent cells (iPSC), and progenitor cells (iMSC) for medical purposes; biological implants, namely, live tissue intended for subsequent implantation; pharmaceutical preparations and drug delivery systems comprising chemical agents and stem cells for the treatment of osteoarthritis, cartilage defects, and cartilage injury; cells, epithelial cells, organoids and cell cultures for personalised medicine, namely, for diagnosis and treatment of diseases or disorders of epithelial tissue in the sensory, reproductive, urinary, digestive, circulatory, endocrine, nervous, lymphatic, integumentary, or respiratory systems; modified stem cells suitable for use as pharmaceutical biologicals used to regenerate neural and spinal cord tissues in humans
First Use Date in General
31st Dec 2021
First Use Date in Commerce
31st Dec 2021
Class [042]
Computer & Software Services & Scientific Services
stem cell research services; research and development services in the field of cytology; custom cell culturing services for scientific and research purposes; testing, inspection, research and development of cell and tissue culturing; research and development of medicines; scientific investigations for medical purposes; custom design and development of chemical reagents scientific services relating to the isolation and cultivation of human tissues and cells for research purposes; research and development and consultation related thereto in the field of antibodies, antibody technology, chemistry, agrochemical pharmaceuticals, bioinformatics, biomedical devices, biologics, biotechnology, biotherapeutics, biology, biochemical preparations, cell lines, chemoinformatic, genetics and genetic engineering, gene expression systems, in vitro research, inhalation pharmaceuticals, molecular sciences, micro-organisms, nutrition, ophthalmic preparations, pharmacogenetics, pharmacokinetics, pharmacology, pharmaceuticals, polymers, peptide synthesis, protein, solid state characterization; scientific and technological services, namely, scientific research, development, analysis, testing, and technological services, namely, scientific research, development, analysis, testing, engineering, extraction, synthesis, purification and production in the field of antibodies, active pharmaceutical ingredients (API), biomolecules, cell bank characterization, chirality, chromosome aberration, clinical chemistry, cloning vector, cyclotides, DNA, flow cytometry, gas chromatography mass spectrometry, gene, immuno-pharmaceuticals, in vitro irritation, large molecule, liquid chromatography mass spectrometry, microbial, monomer, nanoparticle, natural products, peptides, proteins, RNA, supercritical fluid chromatography, small molecules and vaccines; biotechnology research; medical research and development in the field of tissue and cell fabrication; biologic services in the nature of biologic research; biomedical services, namely, laboratory services for human tissue, blood, blood components and stem cells for medical use; medical and scientific laboratory services, namely, development of induced pluripotent stem cells using cells derived from healthy and ill humans; medical and scientific laboratory services, namely, development of induced pluripotent stem cell lines using customized primary cells; medical and scientific laboratory services, namely, evaluating of drugs capable of differentiating various serovars suitable for diseases using induced pluripotent stem cells; medical and scientific laboratory services, namely, evaluating of drug efficacy for technology for making animal models of various diseases; medical and scientific laboratory services, namely, evaluating of the quality of induced pluripotent stem cells; medical services, namely, research services relating to stem cells; research, development and testing services for others in the fields of genomics, biotechnology, chemistry and pharmaceuticals; conducting clinical trials for others in the field of stem cell based therapies and products; scientific research services, namely, tracking, analyzing, forecasting, and reporting data in the field of clinical trials of stem cell based therapies and products
First Use Date in General
31st Dec 2021
First Use Date in Commerce
31st Dec 2021
Mark Details
Serial Number
No 90244106
Mark Type
No Service Mark
Attorney Docket Number
No TUS200045
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 31st May 2022 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| 31st May 2022 | REGISTERED-PRINCIPAL REGISTER |
| 23rd Apr 2022 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| 22nd Apr 2022 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| 22nd Apr 2022 | STATEMENT OF USE PROCESSING COMPLETE |
| 22nd Apr 2022 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| 11th Apr 2022 | USE AMENDMENT FILED |
| 11th Apr 2022 | TEAS STATEMENT OF USE RECEIVED |
| 08th Feb 2022 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| 14th Dec 2021 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |